Shares of Juno Therapeutics Inc (NASDAQ:JUNO) have been given an average rating of “Hold” by the twenty-one ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $57.93.
A number of equities research analysts recently commented on the company. SunTrust Banks reissued a “hold” rating on shares of Juno Therapeutics in a research report on Monday, January 22nd. Raymond James Financial lowered Juno Therapeutics from an “outperform” rating to a “hold” rating in a research report on Tuesday, January 23rd. Leerink Swann lowered Juno Therapeutics from an “outperform” rating to a “market perform” rating and increased their price target for the company from $56.00 to $87.00 in a research report on Tuesday, January 23rd. Barclays lowered Juno Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $55.00 to $87.00 in a research report on Wednesday, January 24th. Finally, Standpoint Research reaffirmed a “hold” rating on shares of Juno Therapeutics in a research report on Wednesday, January 24th.
In related news, CEO Hans Edgar Bishop sold 270,250 shares of Juno Therapeutics stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now owns 2,772,679 shares of the company’s stock, valued at approximately $128,014,589.43. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Robert Azelby sold 1,816 shares of Juno Therapeutics stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $44.96, for a total value of $81,647.36. Following the completion of the sale, the executive vice president now directly owns 70,832 shares of the company’s stock, valued at approximately $3,184,606.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 465,377 shares of company stock valued at $26,375,636. Insiders own 15.08% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company increased its holdings in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares during the last quarter. Advisor Group Inc. increased its holdings in Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares during the last quarter. QS Investors LLC purchased a new stake in Juno Therapeutics in the 2nd quarter worth about $135,000. Bronfman E.L. Rothschild L.P. increased its holdings in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 3,559 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in Juno Therapeutics in the 4th quarter worth about $173,000. 69.13% of the stock is owned by institutional investors.
Juno Therapeutics (JUNO) traded up $0.24 during midday trading on Friday, reaching $85.84. The company had a trading volume of 3,177,384 shares, compared to its average volume of 6,469,508. The stock has a market cap of $9,820.00, a price-to-earnings ratio of -25.29 and a beta of 3.42. Juno Therapeutics has a twelve month low of $19.62 and a twelve month high of $86.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.57) EPS. research analysts anticipate that Juno Therapeutics will post -4.02 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Juno Therapeutics Inc (JUNO) Receives $57.93 Average Target Price from Brokerages” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thestockobserver.com/2018/02/05/juno-therapeutics-inc-juno-receives-57-93-average-target-price-from-brokerages.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.